• Company has resumed exploration on the project, including surface soil sampling and a prospecting campaign
• The exploration program is “designed to lay the groundwork for a future stripping program at Parbec”
• Current MRE is outdated; any future MRE calculated at Parbec will benefit from the inclusion of the new and historic drilling

Renforth Resources (CSE: RFR) (OTCQB: RFHRF), a mineral exploration company engaged in the acquisition, exploration and development of mineral properties in Canada, is reporting on the status of its wholly owned Parbec gold deposit (https://ibn.fm/WFiVB). According to the company, exploration has resumed on the project, including surface soil sampling and a prospecting campaign targeting the southwest portion of the property.

The exploration program is “designed to lay the groundwork for a future stripping program at Parbec, while also investigating previously unexplored areas in the Pontiac sediments, helping to identify additional potential areas for stripping and sampling,” the report stated. “Based on prior surface sampling and drill results, there are two identified target areas for future stripping: the northwest section of the property and the central ‘turning point’ area east of the ramp collar, where the gold-bearing felsites are exposed at surface. Both areas have been previously worked and have yielded surface gold numbers.”

In addition, the company noted that it will sample waste rock generated during the development of the decline. The development, which targeted the hanging wall of the Cadillac Break, was advanced in the early 1980s. “Currently, the decline, which did not reach its goal, is inaccessible and flooded,” the company observed. “However, it did intersect gold-bearing lithologies that were not sampled at the time. Renforth believes it is worthwhile to analyze the untested waste rock that has been stored on-site.”

Parbec is located on the Cadillac Break, Canada’s most productive gold-bearing structure. This very deep structure runs between Kirkland Lake in Ontario and Val d’Or in Quebec, a length of more than 250 km. Next door to Parbec is the Canadian Malartic mine, Canada’s largest open-pit gold mine, located on a proven structure near many gold mines, with road access, power and all the services required to develop the property. This location is very advantageous and cost effective for Renforth.

According to the report, Parbec Gold Deposit hosts a mineral resource estimation (“MRE”) that is not up to date. Since the last calculated MRE, dated May 2020 but effective in December 2019, Renforth has drilled 15,000 meters of new holes, which extended the mineralization within the MRE further down and on an infill basis within the resource model.

“In addition to this, the 2020/21 drilling is considered to have validated an additional 13,000 meters of historic drilling, which Renforth does not have the witness core for, so it was excluded from the 2020 MRE,” the company reported. “The validation of the historic results occurs as 10% of the historic holes were redrilled, with results comparable to the historic hole in terms of geology and gold values in the new holes compared to the old. Any future MRE calculated at Parbec will benefit from the inclusion of the new and historic drilling.”

In addition to its Parbec Gold Deposit Project, Renforth Resources is developing its wholly owned, approximately 330 square kilometer Malartic Metals Package. This project’s surface mineralization includes nickel, cobalt, copper, zinc, silver, gold and lithium in several locations.

For more information, visit the company’s website at www.RenforthResources.com.

NOTE TO INVESTORS: The latest news and updates relating to RFHRF are available in the company’s newsroom at https://ibn.fm/RFHRF

• Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered
• The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS
• CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients
• In MS, CNM-Au8 can work in conjunction with current treatments to improve vision, cognition, and global neural function in MS patients, potentially capturing a significant portion of the MS market as well

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was recently featured on The BioMedWire Podcast, highlighting the important results of CNM-Au8 trials for both amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), and plans for the future (https://ibn.fm/6OOO1).

During the podcast, CEO Rob Etherington explained that Clene is focused entirely on improving mitochondrial health and protecting neuron function, which is “the most important thing we can do to treat neurodegenerative diseases such as ALS, MS, and Parkinson’s.”

Etherington added that having safe and effective therapies to improve function in neurodegenerative disease patients is essential and topical, as the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. “We’re pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases,” he said.

In fact, this approach is one of the key things that set Clene apart from the competition, Etherington said. “Nobody else has theorized that you can drink an oral nanotherapeutic, and that it would do two specific things: improve the mitochondrial dysfunction that is endemic with these diseases, and improve or increase the nicotinamide adenine dinucleotide pathway which is compromised in neurodegenerative diseases.”

Etherington also explained that there is an exigent need for effective therapies for ALS and MS that can improve function, which is something CNM-Au8 has been shown to do in several clinical trials.

“ALS is historically known as Lou Gehrig’s disease, famously named after the baseball player who contracted it in the 1930s. From there, it took 60 years for the first ALS drug to be approved by the FDA, approved in 1995 and still remains today, nearly three decades later, the standard of care. There’s obviously a tremendous need for new drugs in ALS. In the case of multiple sclerosis, there are a lot of drugs that can treat MS, but they all do effectively the same thing: they tamp down the body’s immune response, so the body stops attacking itself. What they don’t do is improve function – the way patients move and walk and talk and think cognitively with MS,” he said.

CNM-Au8 hopes to capture a significant share of the $26 billion therapeutic market for MS, by working in conjunction with existing treatments to enable the energetic capacity that patients’ neurons require to function. In the case of ALS, where the therapeutic market is considerably smaller, CNM-Au8 can help increase and improve survival rates and delay disease progression.

Clene recently announced results of two independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, where participants saw improvement in survival rates and delays in clinical worsening, defined as first occurrence of death (or death and permanent assisted ventilation), tracheostomy, need for invasive ventilatory support, or feeding tube placement. Previous studies investigating CNM-Au8 for MS (Repair-MS and Visionary-MS) also showed significant improvement in global neurological function and vision in stable MS patients, Etherington said.

The company has submitted CNM-Au8 biomarker and clinical efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a New Drug Application (“NDA”) using the accelerated approval regulatory pathway for ALS. A response is expected in the third quarter of 2024. If this accelerated pathway is approved, the next steps will be to file an NDA by the end of the year and to launch a confirmatory global Phase 3 study in ALS.

Etherington also discussed CNM-Au8’s potential as a treatment for other neurodegenerative diseases, including Parkinson’s, Rett syndrome, frontal temporal dementia and Huntington’s, explaining that the drug’s mechanism of action could benefit patients with these conditions as well. The company is also looking at potentially expanding into other disease areas with other therapies once it begins commercializing CNM-Au8, the Clene CEO added.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Transdermal alcohol detection solutions provider SOBRsafe is implementing strategies to further strengthen its financial position
• During Q2 2024, the company eliminated $2.6 million in debt and improved its balance sheet with a capital infusion from the exercise of warrants
• SOBRsafe has increased its revenue by 44% from Q2 2023 as it continues to onboard new customers in 2024

SOBRsafe (NASDAQ: SOBR), the provider of next-generation transdermal alcohol detection solutions, has continued to implement plans and strategies to strengthen its financial position and restructure shareholder equity throughout the second quarter of its 2024 financial year, according to its recent Q2 2024 quarterly update (https://ibn.fm/ZWPa8).

In June the company entered into a Warrant Inducement agreement. The execution of the agreement provided the company with gross proceeds of approximately $2.8 million and net cash proceeds of approximately $2.4 million in exchange for the exercise of 10,319,163 applicable warrants to common shares and issuance of 20,638,326 new plain vanilla warrants to subscribe for and purchase from the company a similar number of shares (https://ibn.fm/63YRz).

The company also settled its remaining debt balances by converting outstanding notes payable into 4,358,957 shares of common stock. Terming these efforts as “very positive developments for the future of SOBRsafe,” Dave Gandini, CEO and Chairman, noted that the company had “significantly strengthened” its balance sheet with the infusion of capital and elimination of $2.6 million in debt.

“With the execution of the company’s strategy to strengthen the balance sheet through the acquisition of liquidity and reduction in future debt obligations, exchange of equity units with unfavorable terms to those conducive to our growth, and in retaining the company’s public market listing, we continue to fortify our financial position and improve our ability to raise capital in the future,” said SOBRsafe CFO Christopher Whitaker in the Q2 2024 update.

In addition to providing a comprehensive update on the status of its financial positioning, SOBRsafe shared its sales progress. In the second quarter of 2024, the company secured 17 customer accounts and, as a result, grew its 2024 new customer count to 33 new accounts, compared to three accounts booked in 2023. The new customers have driven SOBRsafe’s revenue up 44% compared to Q2 2023 figures, to $54,191.

Among the 17 new Q2 customer accounts are two new behavioral health customers, a Texas-based integrative care provider and a Colorado-based recovery services provider, who signed a hardware/software agreement with SOBRsafe (https://ibn.fm/NtsSF). Others include LightHouse Recovery Resources and Mountain House Recovery (https://ibn.fm/Rn44l) as well as a three-facility behavioral health provider (https://ibn.fm/fs4fG), all of whom signed hardware/software agreements.

The recent agreements exemplify the company’s focus on the growing behavioral health market and the progress made since entering this market late last year. “We first entered our core market of behavioral health in Q4 2023, where our technology is re-inventing the continuum of care by reducing redundancy, eliminating paper trails, creating digital records, improving billing processes, and most importantly, creating more time and focus for clinical practice,” said Gandini in the Q2 2024 quarterly update. “Consistent with our sales strategy, we are earning validation in the behavioral health market.”

Gandini noted that the validation it is progressively earning is the “first and most important step” in building its industry brand. Additionally, he went on, it “empowers the range of continued customer adoption – from single location providers with fewer than 25 patients to providers with multiple facilities and larger patient populations.”

SOBRsafe’s growing list of customers relies on its eponymous transdermal technology, which detects and instantaneously reports the presence of alcohol as emitted through a person’s skin. Unlike traditional alcohol monitoring and screening solutions, SOBRsafe’s technology does not require breath, blood, or urine samples.

The company’s alcohol detection technology is fitted into SOBRcheck, its point-of-care alcohol screening device, and SOBRsure, its continuous alcohol monitoring wristband. The technology is also supported by a powerful backend data platform that enables real-time reporting and, depending on the device, GPS tracking.

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

• Torr Metals is establishing itself as a key player in Canada’s booming mining industry, a global leader in the production of over a dozen essential metals
• The company’s emphasis on early-stage district-scale copper and gold projects underscores a significant ground floor opportunity and growth potential within the sector
• Building on early successes by leveraging historical data to expand known mineralization trends, Torr Metals is strategically positioned for potential major new discoveries at Kolos, Filion, and Latham, all within close proximity to established provincial and mining infrastructure

Canada has long been a global leader in the mining industry. Its vast, mineral-rich land, coupled with a stable political and economic climate, has fostered a thriving mining sector. Canada is the 4th largest global gold and 12th copper producer, while also ranking the among the top five producers of aluminum, cobalt, diamonds, fluorspar, gemstones, gold, indium, niobium, palladium, platinum, tellurium, titanium concentrate and uranium.

This type of dominance would not be possible without world-class mining expertise, environmental, social and governance (“ESG”) standards, and infrastructure. This combination of factors has positioned the country as a favored destination for mining investment, with nearly half of the world’s publicly listed mining and mineral exploration companies based in the country.

Torr Metals (TSX.V: TMET) is emerging as a key player in Canada’s mining sector, with a strong focus on early-stage discovery potential that could unlock significant value. Headquartered in Vancouver, British Columbia, Torr is dedicated to advancing its 100% owned, district-scale projects in highly accessible and mineral-rich regions across Canada. These projects are not only poised to contribute to the clean energy revolution with critical minerals like copper but also offer the added economic benefit of potential new major gold discoveries. With existing infrastructure, year-round drilling potential, and low-cost development opportunities, Torr Metals is strategically positioned to capitalize on its exploration successes.

The Projects

Torr’s 140 km² Kolos Copper-Gold Project is strategically located in British Columbia’s prolific Quesnel Trough, an area known for hosting major copper and gold deposits. The project shares geological similarities with successful neighboring mines, including Highland Valley, New Afton, and Copper Mountain. Backstopped by previous exploration efforts, the Kolos project remains largely underexplored, with six kilometer-scale copper and gold soil anomalies identified in 2024 that have never been drill tested, attracting significant potential for new discoveries.

Coincident with these soil anomalies are historical rock grab samples with assays as high as 4.24 grams per tonne (g/t) gold (“Au”), 144 g/t silver (“Ag”), and 1.0% copper (“Cu”). Torr has confirmed and expanded upon the exploration work from the 1960s-1980s through modern techniques. Recent rock grab samples have identified anomalous copper (“Cu”), gold (“Au”), and molybdenum (“Mo”) in outcrops that align with 2023 soil sampling and ZTEM geophysical anomalies that extend up to 1.5 kilometers depth at Kolos. Torr is now preparing for future drill testing with an anticipated permit issuance for late 2024.

The Filion Project covers 261 km² in a highly prospective gold-bearing region of Ontario. Despite historical exploration, the project also remains largely underexplored, offering significant potential for new gold discoveries. The project’s geology is comparable to a multitude of world renown gold mines in the region including the Hemlo deposit, and its accessible location with nearby infrastructure facilitates low-cost operations. Previous exploration identified gold occurrences and promising geological features, but further systematic exploration is required to unlock the project’s full potential. This is precisely the focus of Torr Metals as they advance their exploration efforts.

In July, Torr Metals secured a three-year exploration permit for the Filion Project from the Government of Ontario. Management is currently finalizing plans to be the first to explore what CEO and President Malcolm Dorsey calls “extensive kilometer-scale gold soil anomalies,” which remain untested along trends highlighted by historical high-grade rock and channel samples.

Dorsey specifically noted a significant gold soil anomaly at Filion, discovered last year, which spans 1,200 meters in strike length across multiple conductors and aligns with historical high-grade rock and channel samples. This points to a potential 2.5-kilometer strike length of undrilled gold mineralization. Given the region’s history of multi-million-ounce gold mines, this upcoming drill program is essential for determining if Filion could become northern Ontario’s next major gold discovery.

Torr’s district-scale, 689 km² Latham Copper-Gold Project is located within the famous Golden Triangle region of British Columbia, an area known globally for hosting major high-grade copper-gold deposits. The project encompasses the Gnat Pass deposit, a previously explored copper-gold occurrence with potential for expansion beyond 200 meters vertical depth. In the same theme as Torr’s other projects, historical data is available to leverage and speak to the opportunity, while the breadth of the property remains largely underexplored, with multiple copper-in-soil anomalies and additional mineral occurrences offering significant exploration upside. The project’s proximity to existing mining infrastructure and its location within a highly prospective geological setting create another favorable environment for potential discovery and development.

Setting itself Apart

With its strategically located projects and methodical approach to prove historical data and expand mineralization, Torr has set itself apart in arguably the best country in the world to develop an exploration and mining company. As the global demand for critical minerals continues to rise, the company is well-positioned to capitalize on the opportunities presented by Canada’s abundant resources.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

The Blockchain Futurist Conference, held August 13-14 in Toronto, is Canada’s largest crypto, Web3 and blockchain conference. This year’s highlights included:

• 10,000+ attendees
• 250+ speakers
• 300+ sponsors and partners
• 130+ press and media
• 78 events for CanadaCryptoWeek
• 2 hackathons

Key to the event are panel discussions, which spotlight areas of interest and allow attendees to hear and meet with topic experts. These moderated discussions offer ideas and answers from business and technology leaders who are directly involved in rapidly developing subjects of vital interest.

In particular, this year’s conference offered interested attendees a special panel discussion centering around one of the hottest topics in technology – AI Innovations.

Moderated by Jonathan Keim, Director of Investor Communications for IBN, the discussion brought together technology specialists who are personally involved in lifting AI from hype to happening, and have well-founded views of AI’s real-world direction and potential.

Randall Baran-Chong – Former emerging tech VC partner and director in a global strategy consulting firm
Randall is the lead steward of NorthstarDAO, which evangelizes AI and Web3 to policymakers. He is also the CEO of BizBridge, which helps small businesses find new owners and navigate the merger process with AI agentic technology.

Sheereen Khan – Many years in compliance with 15 years predominantly focused on advocating and educating regulators
Sheereen is the founder and CEO of Regulativity, which is an AI-powered intelligence platform capable of writing compliance policies, notifying personnel as changes take place, and much more.

Jyro Blade – 15 years in video games; 10 years in Web3
Jyro is the product lead at PlayFi which is an AI-powered data network and blockchain tailored for live media content. They are doing incredible things to turn streaming content into actionable data.

The panel discussion centered around where AI is going and what aspects of it are most exciting.

Not surprisingly, AI is seen as taking the place of human effort in roles that are now performed slowly and often inaccurately. This, of course, has always been seen as the natural goal of computer processing; a technology that has developed slowly over the years to its current status as mankind’s ubiquitous assistant.

However, as the panelists pointed out, huge amounts of time are still required for data input and processing is still limited by the strength of traditional algorithms. In other words, there is still the need for technology to take the next step, which includes identifying and extracting necessary data flexibly and then knowing how to organize it for useful output – all with a minimum of human intervention.

AI, with advanced ways of sensing and processing, clearly has the potential for this. But there are challenges. As humans, we learn about the world automatically, simply by living and experiencing, but it takes us years of growing to do it. One of the current issues of developing and working with AI is the amount of time and effort still involved in the overall training process. Having a brain is one thing, but filling it with elaborately interconnected knowledge is another.  Right now, there is still vast amounts of information out there, potentially useful, but which is still not being properly tapped and integrated into the world brain. Humans don’t have the time or connections to do it, and so that is seen as another future goal for AI.

Panelists acknowledged that there is still a lot of hype out there, and some people still criticize AI as not being worth the attention. It’s to be expected with any significant new technology. When personal computers first came out in the 70s and 80s, there were a lot of colorful ads, but the products were expensive and actually did very little. Years later, of course, along with the internet, they clearly revolutionized business and personal productivity. So, there is always hope behind hype. And panelists pointed to the increasing use of AI to make lives better as the final proof.

The ease of using AI, thanks to its flexible capabilities, was another key point discussed. One way to make AI more accessible to a broader audience is through user-friendly interfaces. For instance, voice-to-voice communication with adaptable AI systems requires less time for people to learn and use, making it easier to get value from the technology. As AI becomes more integrated into our lives, it will become increasingly seamless and less noticeable.

Such panel discussions, with individuals who are actually using and applying AI on a daily basis, help tremendously to drive the interest and ultimately the technology.

To learn more about Blockchain Futurist Conference’s upcoming Miami event, visit https://www.futuristconference.com/miami.

• Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration with the National Research Council of Canada (“NRC”)
• The study’s objective was to examine the molecular properties of semaglutide, processed with its patented DehydraTECH(TM) technology, comparing it to Rybelsus(R), the commercially available alternative
• Lexaria’s DehydraTECH demonstrated that semaglutide can be efficiently released in a simulated gastric fluid environment, without the use of salcaprozate sodium (“SNAC”) ingredient chemistry
• This milestone moves the company closer to the diabetes treatment market, projected to hit $153.98 billion in value by 2032

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released findings from its applied research program that sought to evaluate the mode of action facets of its patented DehydraTECH(TM) technology and the glucagon-like peptide 1 (“GLP-1”) drug, semaglutide. The program was conducted in conjunction with the National Research Council of Canada (“NRC”), with the management terming the findings as “positive” (https://ibn.fm/sVTtW).

This marks a significant milestone for Lexaria, mainly since it builds upon its growing dataset around DehydraTECH amenability to GLP-1 formulation and oral delivery performance. In addition, it demonstrates DehydraTECH’s versatility and superiority, notably since the study achieved the desired outcomes without the proprietary salcaprozate sodium (“SNAC”) ingredient chemistry.

The results are significant, since published literature describing Rybelsus(R) noted that it occurs in simple monomeric form in the human gut. This presence has been attributed to SNAC, and the property has been known to allow the permeation of the gastric epithelium to deliver GLP-1 drugs into the bloodstream. Lexaria’s study clearly showed that semaglutide was efficiently released in the simulated gastric fluid environment. In all the cases, it was likely in monomeric form, a form previously achieved using the SNAC technology.

To realize this objective, Lexaria and the NRC team examined the molecular properties of DehydraTECH-processed semaglutide in comparison to the commercially available semaglutide formation, Rybelsus(R). They further used simulated gastric fluid, mimicking conditions in the human gut. In addition, they leveraged various testing methods such as dynamic light scattering (“DLS”), electrospray ionization mass spectrometry (“ESI-LCMS”), polyacrylamide gel electrophoresis (“PAGE”) and size exclusion chromatography (“SEC”).

The findings from this study offer a glimpse into Lexaria’s future. At the beginning of the year, its management noted its commitment to doubling down on GLP-1 studies for 2024, promising to make the year its biggest one yet. This milestone affirms this commitment while highlighting what is in line for Lexaria and its DehydraTECH technology. More importantly, it demonstrates the technology’s potential and versatility,  in delivering various orally administered bioactive molecules more effectively (https://ibn.fm/bhtjL).

Lexaria is making decent headway as it works toward carving out market share in the diabetes treatment market. In 2023, this market was valued at $79.25 billion. It is set to grow to $153.98 billion by 2032, representing a CAGR of 7% over the forecast period (2024-2032) (https://ibn.fm/xSc7M). Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP-1 market.  Its management is bullish about its current direction and is confident that its efforts will pay off in due time.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Electronic monitoring solutions company SuperCom Ltd. provides a suite of products and services to justice system officials worldwide, promoting public safety through the secure tracking of individuals who require supervision
• SuperCom’s PureSecurity technology has the ability to serve a wide variety of tracking purposes but is specifically targeting electronic monitoring of offenders, including domestic violence cases, drug rehabilitation services, and probation orders
• The company recently reported its second quarter and first half financial results, noting growth across multiple metrics, including record profits following a 65.2 percent surge in gross profit and 20.4 percent growth in gross profit margin
• SuperCom’s EBITDA grew by 83 percent in the quarter, and by 182 percent for the first half of the year

Electronic monitoring (“EM”) technology innovator SuperCom (NASDAQ: SPCB) is celebrating impressive developments in 2024, reporting “substantial improvements” in its gross profit, operating income, and net income as it secures new orders and contracts from government and judicial system clients.

SuperCom’s technology development and deployment are strategically focused on providing EM tools for tracking offenders supervised by nations’ crime prevention and rehabilitation infrastructures. The company also provides solutions for a variety of e-government identification services, but its advanced safety technology platform can serve private organizations as well.

The company’s efforts have resulted in a Q2 surge in gross profit (65.2 percent) for a new company record, with net income growth of 183 percent over the previous quarter, according to a news release issued in conjunction with an investor conference call conducted by SuperCom’s executive team August 15.

“Our strategic focus on cost optimization and capital management, combined with our innovative approach to technology deployment, has driven a significant turnaround in our bottom line,” CEO Ordan Trabelsi stated (https://ibn.fm/kjQ4W). “Our ability to reach gross profit margins of nearly 50% as we advance through various stages of our projects is a testament to the efficiency of our operations and the high-margin nature of our offerings.”

The financial report notes that the sales moved SuperCom’s cash flow, net income, and EPS into positive territory, accompanied by 83 percent growth in EBITDA from $0.9 million to $1.6 million.

For the first half of the year, EBITDA improved by 182 percent to $3.6 million, with the gross profit margin nearly doubling to 52.3 percent, operating income improving by $2.8 million, and the net income margin improving to 20.6 percent.

“The recent business wins, including over $11 million in new orders from European governments and several significant new contracts in North America, highlight our leadership in the public safety sector and our ability to penetrate new markets with our cutting-edge solutions,” Trabelsi stated. “Particularly noteworthy is our successful displacement of long-time incumbents in the judicial sector, showcasing the superiority of our PureOne technology. … We are excited about the opportunities ahead and believe in our ability to maintain our momentum.”

The PureSecurity GPS-based suite of hardware, connectivity, and software components is adapted for secured communication. It supports discreet wearing so that monitored individuals can move about the community freely without concerns about the social stigma that might be attached to more obvious ankle monitor devices.

Electronic monitoring doesn’t just improve the community’s safety. It also helps offenders’ function within society in a gainful manner, retaining employment and maintaining a presence within their families while reducing criminal recidivism.

“EM improves the educational attainment and early-life earnings of the children whose parents were exposed to the reform,” a research analysis published by the Journal of Public Economics stated earlier this year (https://ibn.fm/StiyW). “Our calculations suggest that the social benefits stemming from EM are about seven times larger than the fiscal savings associated with reduced prison expenditures, implying that the welfare gains from EM could be much greater than previously acknowledged.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Many renowned luxury brands – fashion houses and watchmakers – honor their equestrian roots and the strong relationship with horses, from Rolex and Longines to Burberry, Gucci, Hermès, and Ralph Lauren
• The companies, which have successfully remained in operation for decades and continue to be influenced by equestrian elements, underscore the proven potential of the luxury equestrian market to build large-scale luxury players
• Beyond an equestrian influence, leading fashion houses emphasize and embody quality, unmatched craftsmanship, and innovation, qualities that ECGI Holdings and its subsidiary Pacific Saddlery have adopted
• A diversified holding company, ECGI Holdings intends to cater to the growing demand for high-quality equestrian apparel through its new collection under the Allon brand, building to broader luxury sectors

In 1901, the then-45-year-old Burberry, now a renowned British luxury fashion house, ran a public competition seeking a winning entry that would become the new logo for the company. The winning entry was the equestrian knight design (“EKD”), a testimony to the company’s relationship with its communities. The EKD depicted an armor-clad knight riding a horse while wielding on one hand a shield emblazoned “B” and on the other, a banner that reads ‘Prorsum’ (Latin for ‘Forward’) (https://ibn.fm/ogj1n).

Since then, the EKD symbol underwent several transformations, with Burberry recently reviving it under the auspices of Daniel Lee, its new creative director, as part of the company’s rebranding efforts. Burberry’s equestrian-inspired logo is one of a few prominent logos that feature a horse and its rider – the others being Hermès and Ralph Lauren.

Founded in 1837 as an artisanal atelier, Hermès (OTC: HESAF) initially made harnesses before expanding its products to include saddles. Today, the company is multifaceted, producing and selling a wide range of luxury goods, apparel, equestrian accessories, and more. Even so, the company has remained true to its roots, retaining its logo depicting a man standing before a carriage-pulling horse (https://ibn.fm/oT69S).

For its part, Ralph Lauren (NYSE: RL) has used its now iconic logo, which depicts a Polo player riding a horse, since the 1970s. The logo tells a larger but perhaps obvious story: equestrianism has been one of the company’s foremost influences. The influence, according to Ralph Lauren, started during the early life of its founder and now permeates to the products the company designs, produces, and sells (https://ibn.fm/DEWju).

For other luxury brands, however, the equestrian influence is not captured in their respective logos but in their products. These include Gucci, which is now part of Kering Group (OTC: PPRUF), and luxury watchmakers Longines, a part of The Swatch Group AG (OTC: SWGAF), and Rolex. Emblematic of their love for equestrianism, the latter two have long partnered with organizers of equine sports competitions around the world to ensure accuracy in sports timekeeping.

The long-standing equestrian histories of these luxury fashion houses and watchmakers point to the lucrativeness of their strong relationships with horses. It is this success, which transcends decades and centuries, that captured the attention and interest of ECGI Holdings (OTC: ECGI), a diversified holding company with a portfolio encompassing viticulture and luxury fashion.

This interest is supported by market research by analysts at Global Market Insights, who forecast that the global equestrian apparel market will reach $9.7 billion by 2032 from $6.5 billion in 2023, representing a 4% CAGR (https://ibn.fm/OmNeU). They also predict that the global equestrian equipment and tack market, valued at $11 billion in 2023, will grow at a 4.3% CAGR to $17 billion in 2032 (https://ibn.fm/1Jj10). Combined, the global equestrian market is expected to be valued at $23.5 billion in 2032 from $17.5 billion in 2023.

To tap into this expected growth while simultaneously acquiescing to its new-found interest, ECGI Holdings strategically invested in Pacific Saddlery Inc., a company that manufactures and sells luxury equestrian tack, apparel, and accessories. The investment is captured in a binding Letter of Intent (“LOI”) announced in June 2024 (https://ibn.fm/bCZvg).

Together, ECGI Holdings and Pacific Saddlery have launched a ready-to-wear equestrian apparel collection under the Allon brand. This collection is intended to cater to the growing demand for high-quality equestrian apparel, aligning with ECGI Holding’s strategy to expand its presence into the luxury equestrian sector (https://ibn.fm/Htnls).

With luxury houses continuously demonstrating that the key to longevity and success, besides the relationship with equestrianism, is innovation, unmatched craftsmanship, and quality, ECGI Holdings and Pacific Saddlery are committed to walking down this proven path, all while cherishing and honoring the influence of horses on fashion.

For more information, visit the company’s website at www.ECGIHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ECGI are available in the company’s newsroom at https://ibn.fm/ECGI

• The company has released key corporate and business updates and Q2 2024 financial results
• Clinical trials for both Alzheimer’s and Parkinson’s studies yielded encouraging data for lead compound buntanetap
• Buntanetap in combination with GLP-1 agonist dulaglutide Trulicity(R) showed increased potential to synergistically enhance cognition
• The company has obtained a patent and begun manufacturing of a new crystalline form of buntanetap, with improved properties

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter ended June 30, 2024. The company reported productive recent months, with encouraging data on lead compound buntanetap’s performance in two pivotal studies, according to Maria Maccecchini, Ph.D., Founder, President, and CEO (https://ibn.fm/hc6L4).

“We’ve completed pivotal Phase 2/3 Alzheimer’s and Phase 3 Parkinson’s studies, both of which revealed very encouraging data for buntanetap,” Maccecchini said. Buntanetap works by targeting multiple pathways involved in neurodegenerative diseases. It inhibits the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression.

Alzheimer’s Disease Clinical Trial:

Data from a Phase 2/3 AD study was released on April 29, showing that buntanetap significantly improved cognition in patients with early AD, with a 3.3-point improvement on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group.

A later analysis on June 11 demonstrated that buntanetap was effective in improving cognition among high-risk APOE4 carriers, showing a 3.15-point improvement. It also showed that buntanetap was as safe in APOE4 carriers as non-carriers, a huge advantage over existing disease-modifying therapies.

Parkinson’s Disease Clinical Trial:

Data from a Phase 3 PD clinical trial was released on July 2, indicating that buntanetap led to significant improvements in both the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and cognition across several PD subpopulations.

Buntanetap showed a strong response in individuals diagnosed with PD for more than three years as well as in those with postural instability and gait disorder (“PIGD”). The lead compound was also found to halt cognitive decline in all enrolled patients and improved cognition in those with mild dementia.

Combination Trial with GLP-1 Agonist Dulaglutide:

On August 6, Annovis Bio released preclinical data demonstrating that its lead compound, buntanetap, synergistically enhances  cognition beyond normal levels, when used in combination with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity(R)) in a mouse model of AD.

New Patents:

The company introduced a new crystalline form of buntanetap with improved properties, further strengthening its IP portfolio. The new crystalline form offers significant advantages over the less structured, old semi-crystalline form, including better solubility and stability as well as an additional 20 years of patent life.

Annovis Bio filed a provisional patent for the manufacturing of this crystalline form.

The company was also granted a patent from the US patent office for using buntanetap for acute traumatic brain injury treatment. The company now has worldwide rights for buntanetap in acute neurodegeneration.

The company received approval from the Food and Drug Administration to continue the development of this new form of buntanetap.

“These milestones position us strongly as we move closer to providing much-needed treatments to patients,” Dr. Maccecchini said, commenting on the business updates.

These encouraging results will enable the company to capture a significant share of the neurodegenerative disease treatment market, an expanding sector driven by an aging population and increasing incidence of conditions like AD. Alzheimer’s care costs are expected to reach $360 billion in 2024 and grow to nearly $1 trillion annually by 2050 (https://ibn.fm/3EpPm).

For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

• A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels
• The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments
• The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations

InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901. These new findings confirm and expand upon results from a previous short-term pilot study (https://ibn.fm/eASUI).

The long-term study, conducted over seven months, utilized the 5xFAD amyloidosis model, extending the dosing duration and increasing the sample size compared to the earlier three-month study. The study included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels. Given the progressive nature of the disease in this model, the groups in the long-term study exhibited more advanced AD than those in the short-term pilot.

The study assessed several behavioral criteria across the four groups. Cognitive function and memory were evaluated using the Novel Object Recognition Test, while general locomotor activity was measured through the Open Field Test. Anxiety-related behavior was gauged using the Elevated and Zero Maze Tests, spatial learning and memory were assessed with the Barnes Maze Test, and sound awareness was tested with the Acoustic Startle Test.

The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments. Significant improvements in specific behavioral criteria were noted compared to the placebo-treated AD groups, reinforcing and in some cases exceeding the outcomes of the short-term study.

Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed, expressed optimism about the findings. “We are highly encouraged by the initial data from this long-term study, which supports the improvements in behavioral outcomes observed in our initial short-term preclinical Alzheimer’s proof-of-concept study. INM-901 continues to show potential by targeting multiple biological pathways associated with Alzheimer’s Disease, addressing the critical need for effective treatments,” Dr. Hsu added.

To better understand the mechanisms of action and the potential role of INM-901 in AD treatment, InMed is conducting further molecular analyses. These analyses will focus on receptor engagement (CB1/CB2 and PPAR), neuroinflammation (levels of various cytokines and inflammatory marker proteins), neurogenesis (markers for neuronal differentiation and function), and neuroprotection (evaluating stress responses and cellular growth/survival).

In addition to these analyses, the development of the chemistry, manufacturing, and controls (“CMC”) for both the drug substance and product formulation is ongoing. GLP studies are in the planning stages to support an IND submission.

Research and development activities to date have demonstrated that INM-901 targets several biological pathways associated with AD, exhibiting positive pharmacological characteristics. These include preferential signaling agonism for CB1/CB2 and impacts on PPAR signaling pathways, blood/brain barrier penetration with potential for oral administration, neuroprotective effects against amyloid-beta-induced cytotoxicity, and promotion of neurite outgrowth, indicating potential improvement in neuronal function.

The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations. InMed Pharmaceuticals continues to advance its research on INM-901, aiming to address the urgent need for effective Alzheimer’s treatments.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM